JP2014516070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516070A5 JP2014516070A5 JP2014514056A JP2014514056A JP2014516070A5 JP 2014516070 A5 JP2014516070 A5 JP 2014516070A5 JP 2014514056 A JP2014514056 A JP 2014514056A JP 2014514056 A JP2014514056 A JP 2014514056A JP 2014516070 A5 JP2014516070 A5 JP 2014516070A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- cycloalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- -1 heterocyclyl-O— Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims description 6
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 0 CC(C)(C1)CN(*)CCC1N(C1CC1)C(*[Al]=C)=O Chemical compound CC(C)(C1)CN(*)CCC1N(C1CC1)C(*[Al]=C)=O 0.000 description 9
- 238000000034 method Methods 0.000 description 2
- GGTZFVAIGQEKIK-UHFFFAOYSA-O CC([NH2+]C)=NC=N Chemical compound CC([NH2+]C)=NC=N GGTZFVAIGQEKIK-UHFFFAOYSA-O 0.000 description 1
- WCGNLBCJPBKXCN-UHFFFAOYSA-N Cc(cc1)cc(F)c1C#N Chemical compound Cc(cc1)cc(F)c1C#N WCGNLBCJPBKXCN-UHFFFAOYSA-N 0.000 description 1
- KUQQONVKIURIQU-UHFFFAOYSA-N Cc(ccc(C#N)c1)c1F Chemical compound Cc(ccc(C#N)c1)c1F KUQQONVKIURIQU-UHFFFAOYSA-N 0.000 description 1
- RNHKXHKUKJXLAU-UHFFFAOYSA-N Cc1ccc(CC#N)cc1 Chemical compound Cc1ccc(CC#N)cc1 RNHKXHKUKJXLAU-UHFFFAOYSA-N 0.000 description 1
- GIWQSPITLQVMSG-UHFFFAOYSA-N Cc1ncc[n]1C Chemical compound Cc1ncc[n]1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169297 | 2011-06-09 | ||
| EP11169297.6 | 2011-06-09 | ||
| PCT/EP2012/060729 WO2012168315A1 (en) | 2011-06-09 | 2012-06-06 | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516070A JP2014516070A (ja) | 2014-07-07 |
| JP2014516070A5 true JP2014516070A5 (enExample) | 2015-07-23 |
| JP6094578B2 JP6094578B2 (ja) | 2017-03-15 |
Family
ID=46245574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514056A Active JP6094578B2 (ja) | 2011-06-09 | 2012-06-06 | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8921398B2 (enExample) |
| EP (1) | EP2718288B1 (enExample) |
| JP (1) | JP6094578B2 (enExample) |
| AR (1) | AR086895A1 (enExample) |
| WO (1) | WO2012168315A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822471B2 (en) | 2011-03-14 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン |
| HK1210825A1 (en) | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP2880027B1 (en) | 2012-08-02 | 2016-09-28 | Boehringer Ingelheim International GmbH | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof |
| KR102040740B1 (ko) * | 2012-09-25 | 2019-11-05 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 제초 및 살진균성 5-옥시-치환된 3-페닐이속사졸린-5-카복사미드 및 5-옥시-치환된 3-페닐이속사졸린-5-티오아미드 |
| PL3798217T3 (pl) | 2016-07-28 | 2023-06-12 | Idorsia Pharmaceuticals Ltd | Piperydynowe modulatory receptora cxcr7 |
| HUE066704T2 (hu) | 2018-01-26 | 2024-08-28 | Idorsia Pharmaceuticals Ltd | CXCR7 receptor antagonista (3S,4S)-1-ciklopropilmetil-4-{[5-(2,4-difluor-fenil)-izoxazol-3-karbonil]-amino} -piperidin-3-karbonsav-(1-pirimidin-2-il-ciklopropil)-amid kristályos formái |
| EP3919489A4 (en) * | 2019-01-31 | 2022-10-12 | The National Institutes of Pharmaceutical R&D Co., Ltd | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND MEDICAL USE |
| WO2025128834A1 (en) * | 2023-12-15 | 2025-06-19 | Alterome Therapeutics, Inc. | Akt1 modulators |
| TW202602878A (zh) * | 2024-03-27 | 2026-01-16 | 美商亞特羅姆醫療公司 | Ａｋｔ１調節劑 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| AU2003277552A1 (en) | 2002-11-06 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor regulator |
| JP2008537953A (ja) | 2005-04-15 | 2008-10-02 | エラン ファーマシューティカルズ，インコーポレイテッド | ブラジキニンｂ１受容体拮抗作用に有用な新規化合物 |
| JP5335426B2 (ja) * | 2005-09-27 | 2013-11-06 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用 |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| ATE476418T1 (de) * | 2006-06-08 | 2010-08-15 | Amgen Inc | Benzamidderivate und assoziierte verwendungen |
| CA2661371A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyrimidine compounds for treating gpr119 related disorders |
| WO2008109702A1 (en) | 2007-03-08 | 2008-09-12 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812649D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| TWI469979B (zh) * | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
| JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| JP5794297B2 (ja) | 2010-05-07 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ１１９アゴニストとしてのピリダジノン |
| UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| UY33871A (es) | 2011-01-21 | 2012-07-31 | Boehringer Ingelheim Int | Compuestos y formulaciones farmacéuticas basadas en derivados de benzo y heteroarilos condensados 2,3-dihidrofurán-2-il-piperidina y sus usos |
| US8822471B2 (en) | 2011-03-14 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン |
-
2012
- 2012-06-06 JP JP2014514056A patent/JP6094578B2/ja active Active
- 2012-06-06 WO PCT/EP2012/060729 patent/WO2012168315A1/en not_active Ceased
- 2012-06-06 EP EP12726611.2A patent/EP2718288B1/en active Active
- 2012-06-06 US US13/489,557 patent/US8921398B2/en active Active
- 2012-06-08 AR ARP120102062A patent/AR086895A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509600A5 (enExample) | ||
| JP2014502988A5 (enExample) | ||
| JP2013545791A5 (enExample) | ||
| JP2017537882A5 (enExample) | ||
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2009534386A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2014525420A5 (enExample) | ||
| JP2016540811A5 (enExample) | ||
| JP2014510147A5 (enExample) | ||
| BR112012001031A8 (pt) | Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência | |
| JP2016530259A5 (enExample) | ||
| RU2011105151A (ru) | Азольные соединения | |
| JP2017508782A5 (enExample) | ||
| RU2005120780A (ru) | Соединения с конденсированным 1,3-дигидроимидазольным циклом | |
| RU2011114487A (ru) | Гетероциклические соединения как ингибиторы протеинкиназы | |
| RU2017139564A (ru) | 5-ароматическое алкинилзамещенное бензамидное соединение и способ его получения, фармацевтическая композиция и их применение | |
| JP2018502148A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2013132930A (ru) | Производное пиразола | |
| JP2017501237A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| IL303962B1 (en) | Modified urea-naphthyridine compounds and a medicament containing the compound | |
| JP2013523814A5 (enExample) |